MD

FORT LAUDERDALE, Fla., July 15, 2026--(BUSINESS WIRE)--Pediatrix Medical Group, Inc. (NYSE: MD) ("Pediatrix" or "the Company"), a leading provider of physician services, today provided an update on its second quarter 2026 business trends. In response to recent reports from other healthcare market participants regarding shifting utilization and reimbursement trends, the Company confirms that its payor mix for the second quarter remained stable and unchanged relative to recent historical trends and the Company’s internal expectations. To date, Pediatrix has not experienced the unfavorable payor mix shifts reported elsewhere in the healthcare sector. In addition, Pediatrix has not seen material changes in other net revenue-related trends compared to recent historical periods. Pediatrix reaffirms its previously reported full year 2026 outlook for Adjusted EBITDA, and anticipates Adjusted EBITDA will be in a range of $280 million to $300 million. Earnings Conference Call Pediatrix will host an investor conference call and webcast on Tuesday, August 4, 2026 at 9:00 a.m. ET to discuss results from operations for the quarter ended June 30, 2026. A detailed press release will be issued the morning of August 4, 2026 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix’s website, www.pediatrix.com/investors. Non-GAAP Measures A reconciliation of projected full year 2026 Adjusted EBITDA to the most directly comparable GAAP financial measures is provided in the financial table of this press release. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Specialties include obstetrics, maternal-fetal medicine and neonatology complemented by multiple pediatric subspecialties. The group’s high-quality, evidence-based care is bolstered by significant investments in research, education, quality-improvement and safety initiatives. The physician-led company was founded in 1979 as a single neonatology practice and today provides its highly specialized and often critical care services through approximately 4,300 affiliated physici...

Elevance Health, Inc. ELV reported second-quarter 2026 adjusted earnings per share (EPS) of $7.45, which surpassed the Zacks Consensus Estimate by 20.6%. However, the bottom line declined 15.7% year over year. Operating revenues advanced 0.8% year over year to $49.8 billion. The top line beat the consensus mark by 2.9%. The quarterly results were primarily driven by higher premium yields in the Health Benefits segment and increased CarelonRx product revenues. The upside was partly offset by a decline in overall medical membership and an elevated expense level. Elevance Health, Inc. price-consensus-eps-surprise-chart | Elevance Health, Inc. Quote As of June 30, 2026, Medical membership of Elevance Health was around 44.9 million, which dipped 1.5% year over year. The decrease was due to the expected loss of some commercial fee-based customers and a decline in Individual ACA and Medicaid membership. The reported figure beat the Zacks Consensus Estimate of 44.8 million and our estimate of 44.5 million. Premiums totaled $41.3 billion in the quarter under review, which remained flat year over year and surpassed our estimate of $39.3 billion. Product revenues grew 3.7% year over year to $6.3 billion, marginally missing the Zacks Consensus Estimate by 0.9% and our estimate by 0.5%. Net investment income rose 44.9% year over year to $704 million. The Adjusted operating margin of 3.6% deteriorated 140 basis points (bps) year over year. Total expenses escalated 2.2% year over year to $48.5 billion in the second quarter, higher than our estimate of $46.7 billion. The year-over-year increase was due to higher cost of products sold, operating expenses and interest expenses. The operating expense ratio was 11.1%, which increased 100 bps year over year. The benefit expense ratio increased 80 bps year over year to 89.7%. Health Benefits The unit recorded operating revenues of $42.7 billion in the second quarter, which rose 2.7% year over year and beat the Zacks Consensus Estimate of $41.2 billion as well as our estimate of $40.7 billion. The segment benefited from increased premium yields. The unit recorded an operating gain of $0.9 billion, which fell 43.8% year over year. It also missed the consensus mark of $1 billion. The operating margin deteriorated 170 basis points year over year to 2.1%. Carelon The segment’s operating revenues rose 6.1% year over year to $19.2 billi...

A month has gone by since the last earnings report for Pediatrix Medical Group (MD). Shares have lost about 1.7% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Pediatrix Medical Group due for a breakout? Well, first let's take a quick look at the latest earnings report in order to get a better handle on the recent drivers for Pediatrix Medical Group, Inc. before we dive into how investors and analysts have reacted as of late. Pediatrix Medical Q1 Earnings Beat Estimates on Same-Unit Strength Pediatrix Medical reported first-quarter 2026 adjusted earnings per share (EPS) of 44 cents, which beat the Zacks Consensus Estimate by 18.9%. The bottom line increased 33.3% year over year. Net revenues increased 3.9% year over year to $476.2 million. The top line exceeded the Zacks Consensus Estimate by 2%. The strong performance was driven by improved reimbursements, along with contributions from recent acquisitions and better same-unit performance. However, these gains were partly offset by lower patient volumes and slightly higher operating costs. Same-unit revenues increased 2.8% year over year, beating the Zacks Consensus Estimate. Same-unit revenues from patient service volumes declined 1.6% year over year. Same-unit revenues from net reimbursement-related factors grew 4.4% year over year. This growth was supported by improved cash collections, higher administrative fees from hospital contracts, more patient cases and a slightly better payor mix. This metric exceeded both the Zacks Consensus Estimate and our model estimate of 1%. Total operating expenses were $434.5 million, up 1.9% year over year. The figure was higher than our estimate of $426.1 million. The year-over-year increase was primarily due to higher depreciation and amortization and general and administrative expenses. Practice salaries and benefits totaled $345.7 million, up 2.6% year over year, mainly due to higher same-unit clinical salary expenses. Interest expense decreased 9.7% year over year to $8.3 million. The figure was below our estimate of $8.9 million due to lower interest rates and borrowings. Adjusted EBITDA rose 18.3% year over year to $58.2 million, driven by favorable same-unit performance and contributions from recent acquisitions. Pediatrix Medical exited the first quarter of 2026 with cash and...

As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the healthcare providers & services industry, including Pediatrix Medical Group (NYSE:MD) and its peers. The healthcare providers and services sector, from insurers to hospitals, benefits from consistent demand, generating stable revenue through premiums and patient services. However, it faces challenges from high operational and labor costs, reimbursement pressures that squeeze margins, and regulatory uncertainty. Looking ahead, an aging population with more chronic diseases and a shift toward value-based care create tailwinds. Digitization via telehealth, data analytics, and personalized medicine offers new revenue streams. Nonetheless, headwinds persist, including clinical labor shortages, ongoing reimbursement cuts, and regulatory scrutiny over pricing and quality. The 40 healthcare providers & services stocks we track reported a strong Q1. As a group, revenues beat analysts’ consensus estimates by 1.4% while next quarter’s revenue guidance was in line. Luckily, healthcare providers & services stocks have performed well with share prices up 10.5% on average since the latest earnings results. With a network of approximately 2,620 affiliated physicians caring for some of the most vulnerable patients, Pediatrix Medical Group (NYSE:MD) provides specialized physician services focused on neonatal, maternal-fetal, pediatric cardiology and other pediatric subspecialty care across 37 states. Pediatrix Medical Group reported revenues of $476.2 million, up 3.9% year on year. This print exceeded analysts’ expectations by 2.6%. Overall, it was a very strong quarter for the company with a beat of analysts’ EPS and revenue estimates. “Our first quarter operating results exceeded our expectations, driven by top-line growth,” said Mark S. Ordan, Chief Executive Officer of Pediatrix Medical Group. The stock is down 3.9% since reporting and currently trades at $21.54. Is now the time to buy Pediatrix Medical Group? Access our full analysis of the earnings results here, it’s free. Transforming how doctors care for seniors by shifting financial incentives from volume to outcomes, agilon health (NYSE:AGL) provides a platform that helps primary care physicians transition to value-based care models for Medicare patients through long-term partnerships and global capitation arrangements. a...

Pediatrix Medical Group, Inc. reported past first‑quarter 2026 results with sales of US$476.2 million and net income of US$29.57 million, both higher than a year earlier, alongside increased basic and diluted earnings per share from continuing operations. Management highlighted that stronger pricing across service lines, improved cash collections, and a healthier payer mix were key drivers of this earnings improvement, reinforcing the importance of operational execution in a complex healthcare reimbursement backdrop. We’ll now examine how this pricing‑driven earnings outperformance shapes Pediatrix Medical Group’s investment narrative and future risk‑reward balance. Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource. To own Pediatrix Medical Group, you need to be comfortable with a story centered on pricing power in neonatal and maternal‑fetal care, while recognizing that reimbursement pressure and labor costs remain the key swing factors. The latest quarter’s pricing‑driven earnings beat supports the near term catalyst of stronger cash generation, but it does not eliminate the underlying risk that hospitals and payers could resist future fee increases or that staffing expenses could outpace revenue growth. The most relevant recent development alongside Q1 is Mizuho’s price target increase to US$24 following the earnings release, which reflects how at least one covering analyst has updated their view on Pediatrix after seeing better pricing and same‑unit revenue trends. For investors, that revision sits against management’s continued capital return via buybacks and acquisitions, which can amplify the impact of any future improvement or deterioration in reimbursement and volume trends. Yet while earnings are improving, investors should also be aware that heavier reliance on pricing power could leave Pediatrix more exposed if... Read the full narrative on Pediatrix Medical Group (it's free!) Pediatrix Medical Group's narrative projects $2.1 billion revenue and $171.4 million earnings by 2029. This requires 2.6% yearly revenue growth and a $6.0 million earnings increase from $165.4 million. Uncover how Pediatrix Medica...

Pediatrix Medical Group, Inc. (NYSE:MD) is one of the best small cap stocks to buy for 10x potential. Mizuho lifted the price target on Pediatrix Medical Group, Inc. (NYSE:MD) to $24 from $21 on May 8, maintaining a Neutral rating on the shares. The rating update came after the company announced financial results for fiscal Q1 2026, reporting earnings of $0.36 per share for the three months ended March 31, 2026. On a non-GAAP basis, adjusted EPS came up to $0.44. Pediatrix Medical Group, Inc. (NYSE:MD) also reported that net income came up to $30 million and adjusted EBITDA was $58 million. Net revenue was $476 million for the quarter compared to $458.4 million for the prior-year period, with the increase reflecting growth in same-unit revenue of 2.8%, and to a lesser extent, growth in non-same unit activity. Management attributed this to recent acquisitions and was partially offset by practice dispositions. In addition, Pediatrix Medical Group, Inc. (NYSE:MD) reported that same-unit revenue from net reimbursement-related factors rose by 4.4% for fiscal Q1 2026, as compared to the prior-year period. Pediatrix Medical Group, Inc. (NYSE:MD) provides physician services, including neonatal care, maternal fetal care, and other pediatric subspecialty care. While we acknowledge the potential of MD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow. Disclosure: None. Follow Insider Monkey on Google News.

Pediatrix Medical Group’s first quarter results surpassed Wall Street’s revenue and profit expectations, yet the market responded negatively, reflecting investor caution around the sustainability of recent drivers. Management highlighted that revenue growth was propelled by strong pricing gains across service lines, driven by robust revenue cycle management and favorable payer mix, despite modest declines in patient volumes. CEO Mark Ordan noted, “We saw strong pricing that outpaced a modest decline in same-unit volumes across our service lines,” with additional contributions from improved contract administrative fees and increased patient acuity in neonatology. While management remains confident in their pricing strategy, they acknowledged ongoing challenges in volume trends and staffing costs. Is now the time to buy MD? Find out in our full research report (it’s free). Revenue: $476.2 million vs analyst estimates of $464.1 million (3.9% year-on-year growth, 2.6% beat) Adjusted EPS: $0.44 vs analyst estimates of $0.38 (16.1% beat) Adjusted EBITDA: $58.15 million vs analyst estimates of $52.23 million (12.2% margin, 11.3% beat) EBITDA guidance for the full year is $290 million at the midpoint, above analyst estimates of $286.7 million Operating Margin: 8.7%, up from 7% in the same quarter last year Same-Store Sales rose 2.8% year on year (6.1% in the same quarter last year) Market Capitalization: $1.87 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Matthew Mardula (William Blair): Asked about future pricing headwinds and whether current growth is sustainable. CFO Kasandra Rossi noted pricing should remain flat for the year, with RCM cash collection benefits expected to taper off in the second half. Matthew Mardula (William Blair): Inquired about ongoing volume declines in NICU days. CEO Mark Ordan replied that while volumes have declined, recent results show stabilization and there is no forecast for renewed declines. Jack Slevin (Jefferies): Asked for additional insights on payer mix and administrative fee trends. Ordan said there are no signs of weakness in payer mix across geographies or service lines, a...

Interested in Pediatrix Medical Group, Inc.? Here are five stocks we like better. Pediatrix Medical Group reaffirmed its full-year 2026 adjusted EBITDA guidance of $280 million to $300 million after a strong first quarter, which produced $58 million in adjusted EBITDA. Revenue gains were driven by 4% pricing growth, improved collections and a favorable payer mix, helping offset modest volume declines across service lines. Management said it has not yet seen weakness from potential health insurance subsidy changes or broader hospital volume softness, though it remains watchful for possible later-year pressure. 3 Reasons Analysts Love DexCom Pediatrix Medical Group (NYSE:MD) reaffirmed its full-year 2026 adjusted EBITDA outlook after reporting what management described as a strong first quarter, supported by higher pricing, improved collections and continued strength in payer mix despite modest volume declines across its service lines. Chair and Chief Executive Officer Mark Ordan said the company generated adjusted EBITDA of $58 million in the quarter. Pediatrix maintained its 2026 adjusted EBITDA guidance range of $280 million to $300 million, even as management acknowledged uncertainty around potential pressure from the lapse of tax subsidies and broader hospital industry volume trends. → Beyond NVIDIA: Picks-and-Shovels AI Plays with Strong Momentum Intuitive Surgical's Selloff Sets Up a 30% Rebound Opportunity “We saw strong pricing that outpaced a modest decline in same unit volumes across our service lines,” Ordan said. “Although recent volume results don't show a trend. Our payer mix continues to be strong.” Ordan said the company remains comfortable not including a headwind estimate tied to the potential effect of the tax subsidy lapse. He noted that while major hospital systems have reported declines in patient volume and revenue, Pediatrix has not yet seen the same weakness in its business. → 3 Ways to Target the Resources Powering AI and Data Centers 5 Spin-Off Stocks That Could Reward Patient Investors in 2026 Chief Financial Officer Kasandra Rossi said consolidated revenue growth was driven by same-unit growth of just under 3% and about $6 million of net non-same-unit activity, including contributions from recent acquisitions and organic growth. That was partially offset by lower revenue tied to portfolio restructuring. Pricing growth of 4% in the...

Pediatrix Medical Group, Inc. MD reported first-quarter 2026 adjusted earnings per share (EPS) of 44 cents, which beat the Zacks Consensus Estimate by 18.9%. The bottom line increased 33.3% year over year. Net revenues increased 3.9% year over year to $476.2 million. The top line exceeded the Zacks Consensus Estimate by 2%. The strong performance was driven by improved reimbursements, along with contributions from recent acquisitions and better same-unit performance. However, these gains were partly offset by lower patient volumes and slightly higher operating costs. Pediatrix Medical Group, Inc. price-consensus-eps-surprise-chart | Pediatrix Medical Group, Inc. Quote Same-unit revenues increased 2.8% year over year, beating the Zacks Consensus Estimate. Same-unit revenues from patient service volumes declined 1.6% year over year. Same-unit revenues from net reimbursement-related factors grew 4.4% year over year. This growth was supported by improved cash collections, higher administrative fees from hospital contracts, more patient cases and a slightly better payor mix. This metric exceeded both the Zacks Consensus Estimate and our model estimate of 1%. Total operating expenses were $434.5 million, up 1.9% year over year. The figure was higher than our estimate of $426.1 million. The year-over-year increase was primarily due to higher depreciation and amortization and general and administrative expenses. Practice salaries and benefits totaled $345.7 million, up 2.6% year over year, mainly due to higher same-unit clinical salary expenses. Interest expense decreased 9.7% year over year to $8.3 million. The figure was below our estimate of $8.9 million due to lower interest rates and borrowings. Adjusted EBITDA rose 18.3% year over year to $58.2 million, driven by favorable same-unit performance and contributions from recent acquisitions. Pediatrix Medical exited the first quarter of 2026 with cash and cash equivalents of $205.8 million, down from $375.2 million as of Dec. 31, 2025. There were no outstanding borrowings on its revolving credit facility at the end of the quarter. Total assets of $2.1 billion decreased from $2.2 billion at the end of 2025. Total debt, including finance leases, net was $590.8 million, which fell from $597.3 million at the end of 2025. Total shareholders’ equity of $878.6 million improved from $865.9 million at the end of 2025. Oper...

Strong first-quarter performance was primarily driven by pricing growth of 4%, which successfully outpaced a modest decline in same-unit volumes across service lines. Pricing strength was supported by four key factors: robust revenue cycle management (RCM) cash collections, increased contract administrative fees, favorable payer mix, and higher patient acuity in neonatology. Management noted that while major hospital systems have reported revenue declines due to tax subsidy lapses, Pediatrix has not yet seen a corresponding headwind in its payer mix. The company is doubling down on clinical quality as a competitive moat, hiring top academic physician leaders to drive data-based care variation reduction and improve patient outcomes. Operational strategy is shifting toward leveraging the company's leading hospital footprint to expand teleservices and obstetrics presence nationwide. The 'Pediatrix Partners' program was launched to align clinician compensation with share price performance, fostering a spirit of ownership among 45 inaugural physician leaders. Management reaffirmed the full-year 2026 adjusted EBITDA guidance of $280 million to $300 million, assuming fairly ratable performance over the remaining three quarters. The company maintains a flat pricing outlook for the full year, anticipating that the significant RCM cash collection benefits seen in Q1 will tail off as the year progresses. Guidance does not currently include a headwind estimate for potential tax subsidy lapses, as management has not yet observed data supporting a negative trend in their specific business lines. Future growth is expected to be supported by a strong balance sheet, with plans to deploy capital toward acquisitions that expand core and emerging service areas. The company will initiate a search for a new General Counsel following the announced retirement of Mary Ann Moore, who serves as both General Counsel and Chief Information Officer, later this year. Practice-level salary, wages, and benefits increased by $9 million, reflecting a 3% average increase in clinical salary expense consistent with the past 18 months. Accounts receivable DSO improved by over five days year-over-year, reaching 42.5 days due to enhanced collection efforts at existing units. The company utilized $21 million in capital to repurchase 1 million shares during the first quarter, ending with a net leverag...

Pediatrix Medical Group (MD) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.37 per share. This compares to earnings of $0.33 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +19.73%. A quarter ago, it was expected that this physician group would post earnings of $0.53 per share when it actually produced earnings of $0.5, delivering a surprise of -5.66%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Pediatrix Medical Group, which belongs to the Zacks Medical Services industry, posted revenues of $476.2 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 1.97%. This compares to year-ago revenues of $458.36 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Pediatrix Medical Group shares have added about 4.8% since the beginning of the year versus the S&P 500's gain of 5.2%. While Pediatrix Medical Group has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Pediatrix Medical Group was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You ca...

FORT LAUDERDALE, Fla., May 05, 2026--(BUSINESS WIRE)--Pediatrix Medical Group, Inc. (NYSE: MD), a leading provider of physician services, today reported earnings of $0.36 per share for the three months ended March 31, 2026. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.44. For the 2026 first quarter, Pediatrix reported the following results: Net revenue of $476 million; Net income of $30 million; and Adjusted EBITDA of $58 million. "Our first quarter operating results exceeded our expectations, driven by top-line growth," said Mark S. Ordan, Chief Executive Officer of Pediatrix Medical Group. "Our priorities for 2026 remain focused on maximizing quality driven support for our hospital partners. With robust cash flow and a healthy balance sheet, we believe we are also well-positioned to find new opportunities and move decisively." Operating Results – Three Months Ended March 31, 2026 Pediatrix’s net revenue for the three months ended March 31, 2026 was $476.2 million, compared to $458.4 million for the prior-year period. This increase reflects growth in same-unit revenue of 2.8 percent, and to a lesser extent, growth in non-same unit activity, driven by recent acquisitions, partially offset by practice dispositions. Same-unit revenue from net reimbursement-related factors increased by 4.4 percent for the 2026 first quarter as compared to the prior-year period. This increase primarily reflects improved cash collections, an increase in hospital contract administrative fees, higher patient acuity, primarily in neonatology, and a slightly favorable shift in payor mix. The percentage of services reimbursed by commercial and other non-government payors increased by 45 basis points compared to the prior-year period. Same-unit revenue attributable to patient volume decreased by 1.6 percent for the 2026 first quarter as compared to the prior-year period. Shown below are year-over-year percentage changes in certain same-unit volume statistics for the three months ended March 31, 2026. (Note: figures in the below table reflect contributions only to net patient service revenue and exclude other contributions to total same-unit revenue, including contract and administrative fees.) For the 2026 first quarter, practice salaries and benefits expense was $345.7 million, compared to $337.0 million for the prior-year period. This increase primarily reflects increas...